Genmab Assumes Command of Key Cancer Drug Program

Genmab (GMAB) has released an update.

Genmab A/S has taken over full control of the acasunlimab development program after BioNTech opted out, continuing the development and potential commercialization independently. Despite BioNTech’s withdrawal for strategic portfolio reasons, Genmab’s robust partnership remains intact, with plans to initiate a Phase 3 study later this year. This shift in responsibilities for the promising cancer treatment candidate does not affect Genmab’s financial outlook for 2024.

For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.